Early trial yields promising results for NIH's dengue vaccine

01/25/2013 | United Press International

A Phase I trial found the NIH's experimental dengue vaccine TetraVax-DV was safe and triggered strong antibody responses in most of the 112 participants. Four combinations were tested, and one called TV003 activated the most balanced response, according to a report in the Journal of Infectious Diseases. More work is needed, but the results are reason for cautious optimism, said National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA